Carlos Panizo

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Topics

Chronic Lymphocytic Leukemia

Prognostic Factors

Ejection Fraction

Diffuse Large B Cell Lymphoma

Top Venues

Journal for immunotherapy of cancer

British journal of haematology

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Sara Rodriguez, Jon Celay, Ibai Goicoechea, Cristina Jiménez, Cirino Botta, Maria-José Garcia-Barchino, Juan-José Garcés, Marta Larrayoz, Susana Santos, Diego Alignani, Amaia Vilas-Zornoza, Cristina Perez, Sonia Garate, Sarai Sarvide, Aitziber Lopez, Hans-Christian Reinhardt, Yolanda R Carrasco, Isidro Sanchez-Garcia, Maria-Jose Larrayoz, María-José Calasanz, Carlos Panizo, Felipe Prosper, José María Lamo-Espinosa, Marina Motta, Alessandra Tucci, Antonio Sacco, Massimo Gentile, Sara Duarte, Helena Vitoria, Catarina Geraldes, Artur Paiva, Noemi Puig, Miriam Santero, Aldo M Roccaro, Gema Fuerte, Jesús San F Miguel, Jose-Angel Martinez-Climent, Juan José Lahuerta
Preneoplastic somatic mutations including MYD88 L265P in lymphoplasmacytic lymphoma. Science advances 8 (3) (2022)
Ascensión López-Díaz de Cerio, Ricardo García-Muñoz, Esther Pena, Ángel Panizo, Jesús Feliu, Pilar Giraldo, Mercedes Rodríguez-Calvillo, Nicolás Martinez-Calle, Carlos Grande, María T Olave, Marcio Andrade-Campos, Eva Bandrés, Jorge M Núñez-Córdoba, Susana I Inoges, Carlos Panizo
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. British journal of haematology 189 (6) (2020)
Ricardo García-Muñoz, Cristina Quero, Ernesto Pérez-Persona, Abel Domingo-García, Cristina Pérez-López, Teresa Villaescusa-de-la-Rosa, Ana M Martínez-Castro, José M Arguiñano-Pérez, Juan F Parra-Cuadrado, Carlos Panizo
Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. British journal of haematology 188 (5) (2019)